About ImmunoGen (NASDAQ:IMGN)
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IMGN
- CUSIP: 45253H10
- Web: www.immunogen.com
- Market Cap: $610.01 million
- Outstanding Shares: 89,597,000
- 50 Day Moving Avg: $6.92
- 200 Day Moving Avg: $5.74
- 52 Week Range: $1.51 - $8.84
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.65
- P/E Growth: 0.00
- Annual Revenue: $83.41 million
- Price / Sales: 6.29
- Book Value: ($1.93) per share
- Price / Book: -3.04
- EBITDA: ($69,450,000.00)
- Net Margins: -117.80%
- Return on Assets: -52.58%
- Debt-to-Equity Ratio: -0.56%
- Current Ratio: 2.40%
- Quick Ratio: 2.34%
- Average Volume: 3.80 million shs.
- Beta: 2.36
- Short Ratio: 5.29
Frequently Asked Questions for ImmunoGen (NASDAQ:IMGN)
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Friday, July, 28th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.07. The company earned $39.02 million during the quarter, compared to the consensus estimate of $30.59 million. The company's revenue was up 426.6% on a year-over-year basis. During the same period last year, the firm posted ($0.53) EPS. View ImmunoGen's Earnings History.
When will ImmunoGen make its next earnings announcement?
Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?
8 equities research analysts have issued 1 year price targets for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they expect ImmunoGen's stock price to reach $8.05 in the next twelve months. View Analyst Ratings for ImmunoGen.
What are analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. Cantor Fitzgerald analysts commented, "IMGN’s speed to market strategy with mirvetuximab soravtansine is intended to advance the drug through the regulatory process by the end of 2020 (FORWARD I), and it is on track." (9/25/2017)
- 2. Cowen and Company analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
- 3. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)
Are investors shorting ImmunoGen?
ImmunoGen saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 12,429,992 shares, a decrease of 37.5% from the August 31st total of 19,881,251 shares. Based on an average daily trading volume, of 4,919,562 shares, the days-to-cover ratio is presently 2.5 days. Approximately 14.3% of the shares of the company are sold short.
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA), Arena Pharmaceuticals (ARNA), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Albany Molecular Research (AMRI), Abeona Therapeutics (ABEO), Heron Therapeutics (HRTX), Crispr Theraptc (CRSP), ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), BeyondSpring (BYSI), WAVE Life Sciences (WVE) and Voyager Therapeutics (VYGR).
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Stephen C. McCluski, Independent Chairman of the Board
- Mark J. Enyedy, President, Chief Executive Officer, Director
- David B. Johnston PhD, Chief Financial Officer, Executive Vice President
- Ellie Harrison, Chief Human Resource Officer, Vice President
- Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
- John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
- Craig Barrows, Vice President, General Counsel, Secretary
- Peter J. Williams, Vice President - Business Development
- Mark A. Goldberg M.D., Independent Director
- Dean Jonathan Mitchell, Independent Director
Who owns ImmunoGen stock?
ImmunoGen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
POLYGON MANAGEMENT LTD.
(5.20%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.
How do I buy ImmunoGen stock?
Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ImmunoGen stock can currently be purchased for approximately $5.86.
Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$8.05 (37.37% upside)|Consensus Price Target History for ImmunoGen (NASDAQ:IMGN)
Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/12/2017||Jefferies Group LLC||Reiterated Rating||Buy||$9.00||N/A|
|9/25/2017||Cantor Fitzgerald||Reiterated Rating||Hold||$5.00||Medium|
|8/30/2017||Canaccord Genuity||Reiterated Rating||Buy||$8.00 -> $10.00||Medium|
|8/29/2017||Cowen and Company||Reiterated Rating||Hold||High|
|8/29/2017||Leerink Swann||Reiterated Rating||Outperform -> Buy||High|
|7/6/2017||Royal Bank Of Canada||Upgrade||Sector Perform -> Outperform||$5.00 -> $12.00||High|
|6/26/2017||William Blair||Reiterated Rating||Outperform||High|
|3/1/2017||Morgan Stanley||Lower Price Target||Underweight||$2.50 -> $1.30||N/A|
|8/5/2016||J P Morgan Chase & Co||Set Price Target||Hold||$9.00 -> $5.00||N/A|
|11/10/2015||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy||$24.00||N/A|
Earnings History for ImmunoGen (NASDAQ:IMGN)Earnings History by Quarter for ImmunoGen (NASDAQ IMGN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/28/2017||Q2 2017||($0.17)||($0.10)||$30.59 million||$39.02 million||View||N/A|
|5/5/2017||3/31/2017||($0.36)||($0.20)||$16.16 million||$28.70 million||View||N/A|
|2/17/2017||Q2 2017||($0.39)||($0.39)||$16.28 million||$13.85 million||View||Listen|
|10/28/2016||Q117||($0.38)||($0.51)||$21.12 million||$7.66 million||View||Listen|
|8/4/2016||Q416||($0.39)||($0.51)||$17.11 million||$7.41 million||View||Listen|
|4/29/2016||Q316||($0.31)||($0.37)||$23.02 million||$19.71 million||View||Listen|
|1/29/2016||Q216||($0.36)||($0.38)||$19.54 million||$18.03 million||View||Listen|
|10/27/2015||Q116||($0.35)||($0.39)||$15.84 million||$14.90 million||View||Listen|
|7/31/2015||Q415||($0.34)||($0.35)||$15.42 million||$12.61 million||View||Listen|
|4/24/2015||Q315||($0.25)||($0.25)||$20.95 million||$11.40 million||View||Listen|
|1/30/2015||Q215||($0.06)||$0.16||$37.30 million||$48.30 million||View||Listen|
|10/24/2014||Q115||($0.14)||($0.26)||$21.80 million||$13.20 million||View||Listen|
|8/1/2014||Q414||($0.36)||($0.31)||$9.72 million||$5.74 million||View||N/A|
|4/25/2014||Q314||($0.27)||($0.44)||$13.28 million||$6.90 million||View||N/A|
|1/31/2014||Q214||($0.18)||($0.29)||$18.16 million||$30.10 million||View||Listen|
|10/25/2013||Q114||($0.23)||($0.13)||$12.10 million||$17.20 million||View||N/A|
|8/2/2013||Q4 2013||($0.30)||($0.26)||$3.44 million||$3.83 million||View||N/A|
|4/26/2013||Q3 2013||($0.15)||($0.02)||$11.94 million||$25.00 million||View||N/A|
|1/25/2013||Q2 2013||($0.25)||($0.29)||$6.02 million||$2.60 million||View||N/A|
|10/26/2012||Q113||($0.25)||($0.30)||$4.10 million||$4.10 million||View||N/A|
Earnings Estimates for ImmunoGen (NASDAQ:IMGN)
2017 EPS Consensus Estimate: ($1.05)
2018 EPS Consensus Estimate: ($1.53)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ImmunoGen (NASDAQ:IMGN)
Insider Ownership Percentage: 6.51%Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Institutional Ownership Percentage: 72.85%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/15/2017||Craig Barrows||VP||Sell||37,050||$6.81||$252,310.50|| |
|9/13/2017||Craig Barrows||VP||Sell||14,600||$6.95||$101,470.00|| |
|12/15/2016||Mark Alan Goldberg||Director||Buy||20,000||$1.80||$36,000.00|| |
|11/8/2016||Mark J Enyedy||CEO||Buy||25,000||$1.83||$45,750.00|| |
|11/2/2016||Craig Barrows||Insider||Buy||10,000||$1.71||$17,100.00|| |
|11/2/2016||Richard J Gregory||VP||Buy||16,600||$1.78||$29,548.00|| |
|2/1/2016||John Lambert||EVP||Sell||3,889||$8.22||$31,967.58|| |
|1/8/2016||Richard J Gregory||VP||Sell||2,369||$11.10||$26,295.90|| |
|1/4/2016||Daniel M. Junius||CEO||Sell||5,416||$13.17||$71,328.72|| |
|1/4/2016||John Lambert||EVP||Sell||3,889||$13.20||$51,334.80|| |
|12/1/2015||Daniel M. Junius||CEO||Sell||5,416||$13.11||$71,003.76|| |
|12/1/2015||John Lambert||EVP||Sell||3,889||$13.11||$50,984.79|| |
|11/27/2015||Charles Q Morris||VP||Sell||5,170||$14.00||$72,380.00|| |
|11/17/2015||Dean J Mitchell||Director||Buy||10,000||$12.51||$125,100.00|| |
|11/2/2015||Daniel M. Junius||CEO||Sell||5,497||$12.00||$65,964.00|| |
|11/2/2015||John Lambert||EVP||Sell||3,889||$11.73||$45,617.97|| |
|10/29/2015||Daniel M. Junius||CEO||Sell||5,335||$12.01||$64,073.35|| |
|10/1/2015||John Lambert||EVP||Sell||3,889||$9.55||$37,139.95|| |
|9/17/2015||David Brannon Johnston||CFO||Sell||5,000||$15.00||$75,000.00|| |
|9/1/2015||Daniel M. Junius||CEO||Sell||5,416||$13.15||$71,220.40|| |
|9/1/2015||John Lambert||EVP||Sell||3,889||$13.16||$51,179.24|| |
|7/1/2015||Daniel M Junius||CEO||Sell||5,416||$14.34||$77,665.44|| |
|7/1/2015||John Lambert||EVP||Sell||3,888||$14.34||$55,753.92|| |
|6/15/2015||Nicole Onetto||Director||Sell||3,211||$13.86||$44,504.46|| |
|6/1/2015||John Lambert||EVP||Sell||15,000||$11.78||$176,700.00|| |
|5/7/2015||Daniel M Junius||CEO||Sell||1,215||$8.02||$9,744.30|| |
|5/1/2015||John Lambert||EVP||Sell||10,000||$8.32||$83,200.00|| |
|11/28/2014||Charles Q Morris||VP||Sell||5,240||$10.40||$54,496.00|| |
|3/17/2014||Daniel Junius||CEO||Sell||15,000||$16.40||$246,000.00|| |
|2/26/2014||Charles Morris||VP||Sell||6,936||$17.35||$120,339.60|| |
|2/20/2014||Charles Morris||VP||Sell||13,672||$17.10||$233,791.20|| |
|2/18/2014||Daniel Junius||CEO||Sell||15,000||$16.26||$243,900.00|| |
|2/3/2014||John Lambert||EVP||Sell||4,375||$14.90||$65,187.50|| |
|1/22/2014||Charles Morris||VP||Sell||7,138||$17.00||$121,346.00|| |
|1/10/2014||Theresa Wingrove||VP||Sell||6,250||$15.04||$94,000.00|| |
|1/2/2014||John Lambert||EVP||Sell||4,375||$14.53||$63,568.75|| |
|12/10/2013||Daniel Junius||CEO||Sell||15,000||$15.11||$226,650.00|| |
|12/2/2013||John Lambert||EVP||Sell||4,375||$14.70||$64,312.50|| |
|11/26/2013||Charles Morris||VP||Sell||12,500||$13.75||$171,875.00|| |
|11/1/2013||John Lambert||EVP||Sell||4,375||$16.41||$71,793.75|| |
|9/10/2013||Gregory D Perry||CFO||Sell||18,337||$17.82||$326,765.34|| |
|9/3/2013||Daniel Junius||CEO||Sell||16,667||$16.43||$273,838.81|| |
|9/3/2013||John Lambert||EVP||Sell||4,375||$16.45||$71,968.75|| |
|8/1/2013||Daniel M Junius||CEO||Sell||16,667||$19.21||$320,173.07|| |
|8/1/2013||John Lambert||EVP||Sell||4,375||$19.21||$84,043.75|| |
|7/11/2013||James J O'leary||VP||Sell||35,000||$19.02||$665,700.00|| |
|7/3/2013||Daniel M Junius||CEO||Sell||16,667||$17.31||$288,505.77|| |
|7/1/2013||John Lambert||EVP||Sell||4,375||$16.80||$73,500.00|| |
|6/3/2013||John Lambert||EVP||Sell||11,250||$17.20||$193,500.00|| |
|5/24/2013||James J O'leary||VP||Sell||28,900||$18.11||$523,379.00|| |
|5/1/2013||John Lambert||EVP||Sell||11,250||$15.56||$175,050.00|| |
|4/11/2013||James J O'leary||VP||Sell||31,100||$17.37||$540,207.00|| |
|11/8/2012||Mark Alan Goldberg||Director||Buy||3,000||$11.27||$33,810.00|| |
Headline Trends for ImmunoGen (NASDAQ:IMGN)
Latest Headlines for ImmunoGen (NASDAQ:IMGN)
Loading headlines, please wait.
ImmunoGen (IMGN) Chart for Monday, October, 23, 2017